Meckel-Gruber Syndrome: a population-based study on prevalence, prenatal diagnosis, clinical features, and survival in Europe by Barisic, Ingeborg et al.
ARTICLE
Meckel–Gruber Syndrome: a population-based study
on prevalence, prenatal diagnosis, clinical features,
and survival in Europe
Ingeborg Barisic*,1, Ljubica Boban1, Maria Loane2, Ester Garne3, Diana Wellesley4, Elisa Calzolari5,
Helen Dolk2, Marie-Claude Addor6, Jorieke EH Bergman7, Paula Braz8, Elizabeth S Draper9,
Martin Haeusler10, Babak Khoshnood11, Kari Klungsoyr12, Anna Pierini13, Annette Queisser-Luft14,
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Meckel–Gruber Syndrome is a rare autosomal recessive lethal ciliopathy characterized by the triad of cystic renal dysplasia,
occipital encephalocele and postaxial polydactyly. We present the largest population-based epidemiological study to date using
data provided by the European Surveillance of Congenital Anomalies (EUROCAT) network. The study population consisted of
191 cases of MKS identified between January 1990 and December 2011 in 34 European registries. The mean prevalence was
2.6 per 100 000 births in a subset of registries with good ascertainment. The prevalence was stable over time, but regional
differences were observed. There were 145 (75.9%) terminations of pregnancy after prenatal diagnosis, 13 (6.8%) fetal deaths,
33 (17.3%) live births. In addition to cystic kidneys (97.7%), encephalocele (83.8%) and polydactyly (87.3%), frequent
features include other central nervous system anomalies (51.4%), fibrotic/cystic changes of the liver (65.5% of cases with post
mortem examination) and orofacial clefts (31.8%). Various other anomalies were present in 64 (37%) patients. As nowadays
most patients are detected very early in pregnancy when liver or kidney changes may not yet be developed or may be difficult to
assess, none of the anomalies should be considered obligatory for the diagnosis. Most cases (90.2%) are diagnosed prenatally
at 14.3±2.6 (range 11–36) gestational weeks and pregnancies are mainly terminated, reducing the number of LB to one-fifth
of the total prevalence rate. Early diagnosis is important for timely counseling of affected couples regarding the option of
pregnancy termination and prenatal genetic testing in future pregnancies.
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INTRODUCTION
Meckel–Gruber Syndrome (MKS) (MKS1 MIM #249000, MKS2
MIM #603194, MKS3 MIM #607361, MKS4 MIM #611134, MKS5
MIM #611561, MKS6 MIM #612284, MKS7 MIM #267010, MKS8 MIM
#613885, MKS9 MIM #614209, MKS10 MIM #614175, and MKS11
#615397) is a genetically heterogeneous severe lethal ciliopathy
characterized by occipital meningoencephalocele and/or other central
nervous system anomalies, polycystic kidneys, and postaxial poly-
dactyly.1–4Additional malformations such as microphthalmia, facial
clefting, heart defects, fibrotic changes in the portal area of the liver,
incomplete/ambiguous development of external or internal genitalia
are often present.2,4–7
The estimated prevalence of MKS worldwide ranges from 1 per
1304 in Gujarati Indians8 to 1 per 140 000 in Great Britain.9 There is
evidence that the prevalence is higher in populations with higher
consanguinity rates, as in India,8,10 Pakistan,11 Kuwait and other Arab
countries.12,13 In Europe, high rates were found in Belgium14 and in
Finland,15 but there are currently no population-based epidemiologic
data available for Europe or worldwide.
MKS is at the severe end of the ciliopathy phenotypic spectrum.
So far, sequence variants affecting function in at least eleven
genes are known to cause this autosomal recessive disorder: MKS1,
TMEM216 (MKS2), TMEM67 (MKS3), CEP290 (MKS4), RPGRIP1L
(MKS5), CC2D2A (MKS6), NPHP3 (MKS7), TCTN2 (MKS8), B9D1
(MKS9), B9D2 (MKS10), TMEM231 (MKS11), and more recently, a
new one has been identified.16 The encoded proteins are all implicated
in the correct function of primary cilia, organelles found on the apical
surface of most epithelial cell types which play an essential role in
cellular function and organ development.17–20
The minimal diagnostic criteria are most often formulated as the
presence of at least two of the three main manifestations, ie bilateral
renal cystic dysplasia, occipital encephalocele or other anomalies of
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the central nervous system, and polydactyly.2–4,21 However, after
review of affected sibs of probands, it has been suggested to
broaden the diagnostic criteria to include as obligatory cystic renal
dysplasia plus at least two other more frequently seen anomalies.5
Salonen6 has suggested to include fibrotic changes of the liver/
ductal proliferation among the major features of MKS, as they are
a consistent finding at post mortem examination. Cystic renal
dysplasia is also found in the vast majority of cases, but in spite of
this, there is still general agreement that there are no mandatory
features of MKS.21,22
As MKS is a rare disease and invariably lethal in early infancy, large
clinical series of patients that address epidemiological and clinical
findings are scarce.4–6 It is possible to detect MKS in the first trimester
of pregnancy and currently most cases are detected prenatally.23,24
However, there is very limited data published on any type of birth
outcomes—live births (LB), fetal deaths (FD), and terminations of
pregnancy after prenatal diagnosis (TOPFA) in MKS patients.
The aim of this study is to investigate MKS, including the
prevalence of the different types of birth outcomes, time of diagnosis,
gender, gestational age (GA), birth weight, associated anomalies,
family history, and consanguinity, using a large European database for
the population-based surveillance of congenital anomalies (EURO-
CAT). To our knowledge, this is the largest series of MKS patients
published so far.
MATERIALS AND METHODS
The EUROCAT congenital anomaly registries are population-based and collect
data on all major structural congenital anomalies, chromosomal abnormalities
and genetic syndromes among LB, FD with GAZ20 weeks, and TOPFA using
standardized definitions and coding. The definitions and coding instructions
were described in previous publications.25–27
The data used in this study were routinely collected between 1990 and 2011
by 34 EUROCAT registries in 16 countries and extracted from the central
database in June 2013. The central EUROCAT database was searched for
International Classification of Diseases/British Paediatric Association version 9
(759.89) and 10 (Q61.90) codes assigned to cases of MKS. The minimal
diagnostic criteria for inclusion in the study were the presence of at least two
of three classic manifestations of MKS.2–5 In EUROCAT registries, clinical
geneticists are involved in the examination and diagnosing of almost all
patients with multiple congenital anomalies and dysmorphic features.28
A medical geneticist (IB) reviewed all records. Textual descriptions were
evaluated to ensure that all relevant clinical information was included in the
study. Local registries were contacted for any additional information required.
For each case, the following data were evaluated: time of diagnosis, outcome of
pregnancy, fetus/infant characteristics including gender, survival up to 1 week
of age, GA (in completed weeks) and birth weight (in grams), associated
anomalies, family history, consanguinity, maternal and paternal age at delivery,
fertility treatment, multiple pregnancy (twin or triplet), post mortem
examination, and karyotype. Data on genetic testing were not systematically
collected. All phenotype and epidemiological data obtained in this study will
be available to public phenotypic databases (eg, Online Mendelian Inheritance
in Man or GeneReviews) upon publication.
Statistical analysis
Descriptive data are presented as numbers and percentages for categorical data.
Mean and 95% confidence interval, based on Poisson distribution, was used
for prevalence. Generalized linear/nonlinear model based on Poisson distribu-
tion was used for statistical testing of time trends in prevalence. A difference
between two proportions test was used for statistical testing of prevalence
differences between registries and total prevalence rate. w2 tests were performed
to determine differences in maternal age distribution between MKS and other
EUROCAT cases. When performing the statistical analyses, a P-value less than
0.05 was considered statistically significant.
RESULTS
Epidemiological data
To ensure a high rate of ascertainment of MKS patients, we have
calculated the prevalence based on data from 16 registries that have
the total non-chromosomal syndrome prevalence above the EURO-
CAT average (7.8 per 1000) following the Data Quality Indicators
developed by EUROCAT (http://www.eurocat-network.eu/content/
DQI-2010.pdf). Between January 1990 and December 2011, in these
registries we monitored a total population of 5 483 380 births and
identified 142 patients with MKS. This corresponds to a prevalence of
1 per 38 615 or 2.6 per 100 000 births. The prevalence rates for 1990–
2000 and 2001–2011 periods were 2.4 and 2.8 per 100 000 births,
respectively (P¼ 0.06) (Table 1). The number of MKS patients per
registry is presented in Table 2.
There were 32 (16.8%) confirmed familial cases, of these there were
27 affected sibs and in five cases, one of the parental relatives had an
anomaly from the MKS spectrum. The consanguinity was recorded in
23 cases according to the EUROCAT definition.26 Almost all
consanguineous cases came from the registries with a statistically
significantly higher prevalence rates of MKS compared with the total
average prevalence for selected registries (Po0.05) (nine from NW
Thames, eight from Paris, four from Vaud, and two families from
Hainaut) (Table 2).
The mean maternal age was 29.3±6.8 years and the mean paternal
age 33.5±7.1 years. Maternal age distribution did not differ
significantly from that for the total EUROCAT population (P¼ 0.06).
Data on karyotyping were available for 94 cases and all results were
normal. Results of post mortem examination were available for 113
(59%) cases six in neonatal deaths and 107 in TOPFA. Multiple
pregnancies of undetermined zygosity were recorded in 6 (3.14%)
cases (only one twin affected). Nine out of 102 (8.8%) patients from
registries that provide the information on assisted reproductive
technology (ART) were conceived by induced ovulation. There were
no cases of in vitro fertilization or intracytoplasmic sperm injection.
Clinical data
Between January 1990 and December 2011, we identified 191 cases of
MKS in the population of 34 European congenital anomaly registries.
Among the patients for which the time of diagnosis was known
(n¼ 183), 90.2% were diagnosed prenatally, 4.9% at birth and 4.9%
in the first week of life. The mean GA at prenatal diagnosis by
obstetric ultrasound was 14.3±2.6 (range 11–36) gestational weeks.
The pregnancies with prenatally diagnosed severe anomalies were
terminated at 18.1±2.53 (range 12–39) gestational weeks. At least two
anomalies (sometimes three or more) were detected by prenatal
ultrasound in all but three cases of renal cystic dysplasia in which at
post mortem additional malformations supporting MKS diagnosis
were found.
The prenatal detection rate was 93.8% (165/176), with no
significant trend over 1990–2000 and 2001–2011 periods (P¼ 0.07).
Table 1 Prevalence of MKS in 16 selected EUROCAT registries,
1990–2011
Monitored period Total births
Total no. of
patients
Birth prevalence per
100000 (95% CI)
1990–2000 2 448 022 58 2.4 (1.9–2.8)
2001–2011 3 035 358 84 2.8 (2.4–3.1)
1990–2011 5 483 380 142 2.6 (2.1–3.0)
Abbreviations: 95% CI, 95% confidence interval; MKS, Meckel–Gruber Syndrome.
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There were 145 (75.9%) TOPFA, 13 (6.8%) FDs, 33 (17.3%) LBs
(Table 3).
The male-to-female ratio was 1.2:1. The mean GA in live born was
34.2±3.4 (range 21–41) gestational weeks for males and 33.9±4.1
(range 28–41) gestational weeks for females. The mean birth weight
was 2540±964 g for males and 2620±246 g for females. Data on
survival were known for 175 patients. Of 33 live born, only six
survived the first week of life.
Detailed description of congenital anomalies was available for 173
patients. The type and frequency of major congenital anomalies in the
present study and in the larger series of MKS patients published so far
are shown in Table 4. In addition to cystic kidneys (97.7%),
encephalocele (83.8%) and polydactyly (87.3%), frequent features
include other central nervous system anomalies (51.4%), fibrotic/
cystic changes of the liver (65.5% of cases with post mortem
examination) and orofacial clefts (31.8%).There were 64 (37%)
patients with anomalies other than the classical triad. Among these
64 patients, one additional associated major anomaly was present in
29 (16.8% of the total population), two anomalies in 21 (12.1%), and
three or more associated anomalies in 14 (8.1%) patients.
DISCUSSION
Prevalence
Although MKS has been reported worldwide, more extensive data on
the true prevalence in different populations are rare. In Europe,
hospital-based prevalence has been reported for Belgium (1 per
3 408)14 and Great Britain (1 per 140 000)9 and population-based for
Finland (1 per 9000).15 In our population-based study, the prevalence
of MKS in 16 selected EUROCAT registries is 2.6 per 100 000 or 1 per
38 615 births and that prevalence has been stable since 1990. MKS
includes severe and distinctive anomalies that are easily detected
prenatally or at birth. Therefore, it is unlikely that a significant
number of cases were missed. It is, however, possible that some of the
fetuses with atypical presentation were terminated or resulted in
stillbirth without syndrome diagnosis, particularly when there was no
post mortem examination. Therefore, the established prevalence
represents a minimal estimate.
There is heterogeneity in the prevalence rates, with significantly
higher rates in Hainaut (Belgium), Paris (France), Vaud (Switzerland),
NW Thames (UK) and Thames Valley (UK), Presumably, in the
regions with a higher prevalence rate, there are families residing with
the mutated genes as most of the consanguineous cases come from
there. The highest prevalence rate was observed in Vaud (Switzerland)
(1 per 15 177 births).
As expected, no correlation with maternal or paternal age was
found. The number of multiple pregnancies was within the normal
range for EUROCAT registries.29 MKS was previously described
following ART30,31 and epidemiologic surveillance of rare autosomal
recessive syndromes, such as MKS, in ART pregnancies was
proposed.31 In our study, no association of MKS and ART was
observed when compared with the data for general European
population.32
Clinical presentation
MKS is a lethal disorder. Most infants are stillborn or die within a few
hours or days after birth. The majority of prenatally detected cases in
our series were subsequently terminated due to the presence of severe
anomalies (88%). Therefore, we did not observe a high rate of FD.
Only 17.3% of patients were live born. About two-thirds of live born
of both sexes had GA at birthr37 gestational weeks and birth weight
o2 500 g. The male-to-female ratio was equal.This is in accordance
with an autosomal recessive inheritance and previous observations.4
The longest known survival recorded in the literature is 28
months.33,34 The major causes of early death include impaired
kidney function with subsequent oligohydramnios, pulmonary
hypoplasia, and liver disease. In our study from 17 LB with
recorded survival, only six (35.2%) survived the first week of life.
MKS is characterized by central nervous system malformation
(usually occipital encephalocele), bilateral large multicystic kidneys,
fibrotic changes of the liver, and polydactyly.1–6,35 In addition to the
characteristic anomalies, other congenital anomalies are frequently
found, leading to a wide phenotypic variation. The differential
diagnosis of fetuses and infants with these multiple anomalies
would include trisomy 13, Smith-Lemli-Opitz, hydrolethalus
(Salonen-Herva-Norio), Joubert and Bardet Biedel syndromes.6,7
The diagnosis is clear in most instances because of the distinctive
combination of the key features. Additional conditions that could
present a diagnostic challenge include Joubert syndrome and related
disorders (probably allelic ciliopathies), acromelic frontonasal
dysplasia, oral–facial–digital syndromes type 1 and 2, cerebro–reno–
digital syndrome, Mullerian duct/Renal aplasia–cervicothoracic
Table 2 The number of cases and prevalence of MKS patients in 16
selected EUROCAT registries in 1990–2011
Registry
No. of MKS patients in
1990–2011 Population
Prevalence per
100000
Styria (Austria) 1 229 506 0.4
Antwerp (Belgium) 8 341 573 2.3
Hainaut (Belgium) 8 277 204 2.9a
Dublin (Ireland) 1 489 614 0.2
Odense (Denmark) 0 121 532 0
Paris (France) 35 703 650 5a
Strasbourg (France) 4 230 664 1.7
Mainz (Germany) 1 75496 1.3
Cork And Kerry (Ireland) 1 131 119 0.8
N Netherlands (Nl) 10 421 026 2.4
Vaud (Switzerland) 11 166 950 6.6a
Northern England (UK) 9 382 900 2.3
N W Thames (UK) 22 661 527 3.3a
Thames Valley (UK) 11 291 759 3.8a
Wales (UK) 10 466 301 2.1
Wessex (UK) 10 492 559 2
Total 142 5 483 380 2.6
Abbreviations: EUROCAT, European Surveillance of Congenital Anomalies; MKS, Meckel–Gruber
Syndrome.
aRegistries with statistically significant higher prevalence rates compared to the total average
prevalence rate of selected registries (Po0.05).
Table 3 Outcome of pregnancies and prenatal detection rate in MKS
in the EUROCAT registries, 1990–2011
Monitored
period
Total
no. of
patients LB FD TOPFA
Prenatally detected/
number of patients
with available data
Prenatal detection
rate % (95% CI)
1990–2000 72 13 4 55 60/66 91 (86.5–95.7)
2001–2011 119 20 9 90 105/110 95.5 (89.1–98.0)
1990–2011 191 33 13 145 165/176 93.8 (89.1–98.4)
Abbreviations: 95% CI, 95% confidence interval; EUROCAT, European Surveillance of
Congenital Anomalies; FD, fetal deaths; LB, live born; MKS, Meckel–Gruber Syndrome;
TOPFA, terminations of pregnancy for fetal anomaly.
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Table 4 Type and frequency of major anomalies in MKS in present study and in previously published reviews/series of patients
Patients Salonen6 Fraser and Lytwyn5 Hsia et al4
Type of anomaly N¼173(%) N¼67(%) N¼65(%) N¼51(%)
Nervous system
Encephalocele 145 (83.8) 57/64 (89)
Encephalocele—occipital 99 (57.2) 48 (74) 41 (80.4)
Encephalocele—nasophrontal 1 (0.6)
Encephalocele—orbital 1 (0.6)
Encephalocele—NOS 44 (25.4)
Cervical rachishisis 4 (2.3) 4 (6)
Microcephaly 4 (2.3.) 41/65 (63)a 25 (49)
Anencephaly 6 (3.5) 8 (12.3)
Holoprosencephaly 5 (2.9)
Agenesis/hypoplasia of corpus callosum 3 (1.7)
Dandy Walker anomaly 23 (13.3)
Arnold Chiari anomaly 2 (1.2)
Agenesis/hypoplasia of cerebellum 11 (6.4) 7 (10.4)
Atretsia of foramina Magendi and Luschka 3 (1.7)
Congenital cerebral cyst 2 (1.2)
Congenital hydrocephalus 14 (8.1) 11/64 (17) 10 (15.4)
Other 12 (6.9) 4 (6) 20 (30.8) 30 (58.9)
Head and neck
Eye 18 (27.7)
Lid anomalies 2 (1.2)
Microphthalmia/anophthalmia 35 (20.2) 16/61 (26) 13 (25.4)
Retinal dysplasia 3 (1.7)b
Coloboma 1 (0.6)
Anomalies of tongue 13 (7.5) 9/61 (15)
Orofacial clefting 44 (25.4) 20 (30.8) 29 (56.9)
Cleft palate 34 (19.7) 27/42 (64)
Cleft lip 10 (5.8) 12/62 (19)
Cleft lip and palate 11 (6.4)
Respiratory
Lung/thorax hypoplasia 12 (6.9) 19 (28)
Heart 28 (16.2) 11/56 (20) 21 (32.3) 10 (19.6)
Ventricular septal defect 9 (5.2) 2 (3)
Atrial septal defect 4 (2.3) 6 (9)
Stenosis of pulmonar artery 2 (1.2)
Persistent left superior vena cava 2 (1.2)
Double outlet right ventricle 1 (0.6)
Dextrocardia 1 (0.6)
Coarctation of aorta 2 (1.2)
Common ventricle 1 (0.6)
Congenital heart disease, NOS 6 (3.5)
Digestive 11 (21.6)
Anomalies of intestinal fixation 3 (1.7)
Fibrotic and/or cystic liver/ductal plate malformation 74 (65.5)c 47/47 (100) 25 (38.5)
Anal stenosis/atresia 7 (4)
Omphalocoele 3 (1.7)
Persistent cloaca 1 (0.6)
Spleen anomaly 6 (3.5) 6 (9) 12 (18.4) 6 (11.8)
Adrenal 2 (1.2) 8 (11.9) 6 (9.2) 8 (15.7)
Kidney
Cistic kidney disease 169 (97.7) 55/55 (100) 65 (100) 41 (80.4)
Renal agenesis 6 (3.5)
Renal hypoplasia/dysplasia 24 (13.9)
Accessory kidney 2 (1.2)
Ren arcuatus 2 (1.2)
Other anomalies, NOS 8 (4.6)
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somite dysplasia syndrome, and renal–hepatic–pancreatic dysplasia—
Dandy Walker cyst syndrome. Additional investigations, in particular
histopathologic studies, molecular testing, and karyotype are of help
in clarifying atypical cases, but in the absence of the simple and
reliable genetic test, there is always a possibility of the wrong
diagnosis. Genetic mapping is probably still incomplete, although
mutations in about dozen genes are reported to be pathogenic. The
genotype–phenotype correlations and identification of founder muta-
tions in specific ethnic groups are in progress.17,36,37 In EUROCAT,
systematic data collection has only started recently for the results of
genetic testing and thus, this study is not able to contribute to this
effort.
The cystic kidneys are reported in 95–100%, occipital encephalocele
in 60–80%, and postaxial polydactyly in 55–75% of patients.2–6 Our
results are in line with these findings. Cystic kidney dysplasia was the
most constant feature in our study, although it was not present in all
patients. This is in contrast with the assumption of some authors that
cystic kidneys are an obligatory finding in MKS.5 Similarly, we
recorded liver fibrosis and proliferation of bile ducts in 65.5% of
cases in which pathological examination was performed. This is
considerably less in comparison with a series of patients reported by
Salonen,6 in which all patients had liver lesions on post mortem
examination. Both findings could be explained by the fact that our
series of patients differed significantly from those reported in the
literature so far. Whereas all patients investigated by Salonen6 died
immediately before, during, or after birth, most of the patients in our
series were ascertained in the first trimester of pregnancy. It is possible
that some of the pathological changes were not clearly visible or fully
developed and thus were difficult to diagnose in TOPFA, which
accounted for 75.9% of cases. For the same reason, some anomalies
appearing later in pregnancy (eg, hydrocephalus) were observed less
frequently.
The encephalocele was mostly occipital. Other central nervous
system anomalies ranging from mild to severe were also frequently
recorded. In particular, we observed a higher rate of different degrees
of cerebellar hypoplasia and dysgenesis of posterior fossa structures
including Dandy Walker anomaly. These anomalies are presumably
due to the impairment of Sonic hedgehog-dependent proliferation of
granule cell progenitors in MKS and Joubert syndrome patients.17
Postaxial polydactyly, the most variable of the three major
presentations, typically affects all four limbs but in our sample only
hands or feet were affected in 31 and 20 cases, respectively.
Other more frequently observed anomalies included cleft lip/palate,
microphthalmia, congenital heart defects, genital anomalies, and
skeletal defects. All types of recorded anomalies were previously
described in MKS patients, with the exception of omphalocele that we
recorded in three patients, a case of persistent cloaca and a case of
limb reduction defect (agenesis of humerus and femur).
The lower rate of microcephaly, club foot, and lung hypoplasia in
our series of patients is explained by the fact that these anomalies are
considered to be a sequence of encephalocele and oligohydramnios,
respectively, and as such not regarded as anomalies of their own
according to the EUROCAT coding rules.
Prenatal diagnosis
Prenatal ultrasound diagnosis of MKS is possible from 11–14 weeks of
gestation, based on the observation of two out of the three major
anomalies in the fetus.24 The early demonstration of an unusual
Table 4 (Continued )
Patients Salonen6 Fraser and Lytwyn5 Hsia et al4
Type of anomaly N¼173(%) N¼67(%) N¼65(%) N¼51(%)
Urinary 18 (10.4) 29/54 (54) 9 (13.8)
Congenital hydronephrosis 4 (2.3)
Double ureter 2 (1.2)
Anomalies of bladder 4 (2.3)
Other anomalies, NOS 8 (4.6)
Genital 40 (23.1) 18 (27.7)
Uterus duplex 3 (1.7)
Unicornuate uterus 4 (2.3)
Uterus bifidum 6 (3.5)
Hypoplastic scrotum 9 (5.2)
Ambiguous genitalia 18 (10.4) 9 (13.4) 22 (43)
Skeletal
Pes equinovarus 15 (8.7) 32/62 (52)
Polydactyly legs 122 (70.5) 58/64 (91)
Polydactyly hands 133 (76.9) 61/64 (95)
Polydactyly unspecified 18 (10.4)
Polydactyly total cases 151 (87.3) 44 (67.7) 42 (82)
Syndactyly 6 (3.5) 5 (7.5) 7 (13.7)
Limb reduction 1 (0.6)
Short limbs 33 (19) 18 (26.9) 14 (27.5)
Abbreviations: MKS, Meckel–Gruber Syndrome; NOS, not otherwise specified.
Please note that in all studies the rate of each congenital anomaly is calculated using as denominator the total number of cases and not the number of performed appropriate diagnostic
procedures.
NOS, individuals with more than one anomaly within a category were counted only once.
aMicrocephalyþ anencephaly.
bTwo recorded in SB and one in LB.
cRecorded in 74/113 post mortem reports.
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corticomedullary differentiation and appearance of small pyramidal
cysts during the first trimester and early second trimester are
considered to be significant distinguishing features.23 Later in
pregnancy, the diagnosis may be more difficult because of the
oligohydramnios. The presence of oligohydramnios, invisible
bladder, and discrepancy in the biparietal and abdominal diameter,
however, can lead to the diagnosis.6,7,23,38 Fetal magnetic resonance
imaging can be used as a complementary method when findings
are inconclusive or equivocal.39 This is the first study to provide
population-based data on prenatal diagnosis and termination of
pregnancy for MKS. Prenatal detection rate of major anomalies
characteristic of MKS by prenatal ultrasound examination was 93.4%.
The mean GA at diagnosis was 14.3 gestational weeks. The prenatal
detection rate did not substantially change during the study period.
Prenatal diagnosis resulted in termination of pregnancy in
approximately two-thirds of all cases, which shows the important
impact of prenatal diagnosis on the outcome of MKS pregnancies in
Europe.
Study strengths and limitations
This is the only epidemiological population-based study and the
largest series of MKS patients published to date. The main
strengths of this study are the large population that includes all
types of pregnancy outcomes, standardized data collection and the
use of genetic expertise in patient evaluation and coding. However,
when combining epidemiological data from many different regis-
tries, certain variation due to coding practices, completeness and
accuracy of case description must be taken into consideration. Post
mortem results were unavailable for some patients, which could be
the reason for underreporting of some anomalies not detected by
prenatal ultrasound. Certain anomalies are difficult to diagnose in
a post mortem following a TOPFA, which accounted for about
two-thirds of cases in our series. Finally, some of the cases
registered in EUROCAT database as isolated encephalocele or
isolated bilateral renal cystic dysplasia for which the post mortem
examination was not performed or was negative for other key
defects because of the early termination of pregnancy, could be
unrecognized MKS cases.
In conclusion, MKS is a rare genetic disorder with the minimal
total prevalence of 2.6 per 100 000 births in Europe. The prevalence is
stable, but regional differences due to characteristics of resident
populations are observed. Cystic kidneys and fibrous dysplasia of
the liver are probably present in all cases at birth, but as nowadays
most patients are detected very early in pregnancy, these changes may
not yet be developed or may be difficult to assess. Consequently, at
present, they should not be considered obligatory for the diagnosis of
MKS. Most of the cases are suspected prenatally due to the presence
of characteristic severe anomalies, and pregnancies are mainly
terminated, reducing the number of LB to one-fifth of the total
prevalence rate. Parents should be counseled about the high mortality
and morbidity and poor prognosis for survival. Early diagnosis is
important for the timely counseling of affected couples regarding
their decision on pregnancy termination. In view of the high
recurrence risk, detailed investigation by first trimester ultrasound
scans and the possibility of prenatal genetic testing from chorionic
villi sampling in subsequent pregnancies should also be discussed.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
ACKNOWLEDGEMENTS
This study is a part of the EUROCAT Joint Action funded by the EC, under the
framework of EU Health Programme 2008–2013, Grant Agreement 20102204
(Executive Agency for Health & Consumers). We thank doctors Larraitz
Arriola, Sebastiano Bianca, Jean Chapple, Berenice Doray, Christine
Francannet, Miriam Gatt, Anna Latos-Bielenska, Bob McDonnell, Carmen
Mosquera-Tenreiro, Vera Nelen, Mary O’Mahony, Catherine Rounding,
Joaquin Salvador, Gioacchino Scarano, David Stone, Romano Tenconi, David
Tucker, for providing data for the present study. We also thank the many
people throughout Europe involved in providing and processing information,
including affected families, clinicians, health professionals, medical record
clerks, and registry staff.
1 Meckel JF: Beschreibung zweier, durch sehr aehnliche Bildungsabweichungen
entstellter Geschwister. Dtsch Arch Physiol 1822; 7: 99–172.
2 Opitz JM, Howe JJ: The Meckel syndrome (dysencephalia splanchnocystica, the Gruber
Syndrome). Birth Defects 1969; 2: 167–179.
3 Mecke S, Passarge E: Encephalocele, polycystic kidneys, and polydactyly as an
autosomal recessive trait simulating certain other disorders: the Meckel syndrome. Ann
Genet 1971; 14: 97–103.
4 Hsia YE, Bratu M, Herbordt A: Genetics of the Meckel syndrome (dysencephalia
splanchnocystica). Pediatrics 1971; 48: 237–247.
5 Fraser FC, Lytwyn A: Spectrum of anomalies in the Meckel syndrome, or: "Maybe there
is a malformation syndrome with at least one constant anomaly". Am J Med Genet
1981; 9: 67–73.
6 Salonen R: The Meckel syndrome: clinicopathological findings in 67 patients. Am J
Med Genet 1984; 18: 671–689.
7 Alexiev BA, Lin X, Sun CC, Brenner DS: Meckel-Gruber Syndrome: pathologic
manifestations, minimal diagnostic criteria, and differential diagnosis. Arch Pathol
Lab Med 2006; 130: 1236–1238.
8 Young ID, Rickett AB, Clerke M: High incidence of Meckel’s syndrome in Gujarati
Indians. J Med Genet 1985; 22: 301–304.
9 Seller MJ: Meckel syndrome and the prenatal diagnosis of neural tube defects. J Med
Genet 1978; 15: 462–465.
10 Panduranga C, Kangle R, Badami R, Patil PV: Meckel-Gruber Syndrome: report of two
cases. J Neurosci Rural Pract 2012; 3: 56–59.
11 Crawfurd Md’A, Jackson P, Kohler HG: Meckel’s syndrome (dysencephalia splanchno-
cystica) in two Pakistani sibs. J Med Genet 1978; 15: 242–245.
12 Farag TI, Usha R, Uma R, Mady SA, al-Nagdy K, el-Badramany MH: Phenotypic
variability in Meckel-Gruber Syndrome. Clin Genet 1990; 38: 176–179.
13 Teebi AS, Al Saleh QA, Odeh H: Meckel syndrome and neural tube defects in Kuwait.
J Med Genet 1992; 29: 140.
14 Moerman P, Verbeken E, Fryns JP, Goddeeris P, Lauwcryns JM: The Meckel syndrome.
Pathological and cytogenetic observations in eight cases. Hum Genet 1982; 62:
240–245.
15 Salonen R, Norio R: The Meckel syndrome in Finland: epidemiologic and genetic
aspects. Am J Med Genet 1984; 18: 691–698.
16 Shaheen R, Shamseldin HE, Loucks CM et al: Mutations in CSPP1, encoding a core
centrosomal protein, cause a change of ciliopathy phenotypes in humans. Am J Hum
Genet 2014; 94: 73–79.
17 Aguilar A, Meunier A, Strehl L et al: Analysis of human samples reveals impaired
SHH-dependent cerebellar development in Joubert syndrome/Meckel syndrome.
Proc Natl Acad Sci USA 2012; 109: 16951–16956.
18 Shaheen R, Ansari S, Mardawi EA, Alshammari MJ, Alkuraya FS: Mutations
in TMEM231 cause Meckel-Gruber Syndrome. J Med Genet 2013; 50:
160–162.
19 Abdelhamed ZA, Wheway G, Szymanska K et al: Variable expressivity of ciliopathy
neurological phenotypes that encompass Meckel-Gruber Syndrome and Joubert
syndrome is caused by complex de-regulated ciliogenesis, Shh and Wnt signalling
defects. Hum Mol Genet 2013; 22: 1358–1372.
20 Barker AR, Thomas R, Dawe HR: Meckel-Gruber Syndrome and the role of primary cilia
in kidney, skeleton and central nervous system development. Organogenesis 2013; 10:
96–107.
21 Lowry RB, Hill RH, Tischler B: Survival and spectrum of anomalies in the Meckel
syndrome. Am J Med Genet 1983; 14: 417–421.
22 Wright C, Healicon R, English C, Burn J: Meckel syndrome: what are the minimum
diagnostic criteria? J Med Genet 1994; 31: 482–485.
23 Ickowicz V, Eurin D, Maugey-Laulom B et al: Meckel-Gruber Syndrome: sonography
and pathology. Ultrasound Obstet Gynecol 2006; 27: 296–300.
24 Eckmann-Scholz C, Jonat W, Zerres K, Ortiz-Bru¨chle N: Earliest ultrasound findings
and description of splicing mutations in Meckel-Gruber Syndrome. Arch Gynecol
Obstet 2012; 286: 917–921.
25 EUROCAT website. Available at: http://www.eurocat-network.eu/.
26 EUROCAT ‘Guide 1.3’. Available at: http://www.eurocat-network.eu/ABOUTES/
DataCollection/GuidelinesforRegistration/Guide1_3InstructionManual.
27 EUROCAT ’Members & Registry Descriptions’. Available at: http://www.eurocat-
network.eu/ABOUTES/MemberRegistries/MembersAndRegistryDescriptions/AllMembers.
Meckel-Gruber Syndrome
I Barisic et al
6
European Journal of Human Genetics
28 Barisic I, Tokic V, Loane M et al: Descriptive epidemiology of Cornelia de Lange
syndrome in Europe. Am J Med Genet 2008; 146: 51–59.
29 Boyle B, McConkey R, Garne E et al: Trends in the prevalence, risk and pregnancy
outcome of multiple births with congenital anomaly: a registry-based study in 14
European countries 1984-2007. BJOG 2013; 120: 707–716.
30 Shozu M, Akimoto K, Tanaka J, Sonoda Y, Inoue M, Michikura Y: Antenatal detection of
Meckel-Gruber Syndrome in only one dizygotic twin following in vitro fertilization and
embryo transfer. Gynecol Obstet Invest 1997; 43: 142–144.
31 Celentano C, Prefumo F, Liberati M, Gallo G, Di Nisio Q, Rotmensch S: Prenatal
diagnosis of Meckel-Gruber Syndrome in a pregnancy obtained with ICSI. JAssist
Reprod Genet 2006; 23: 281–283.
32 de Mouzon J, Goossens V, Bhattacharya S et al: Assisted reproductive technology in
Europe, 2007: results generated from European registers by ESHRE. Hum Reprod
2012; 27: 954–966.
33 Ramadani HM, Nasrat HA: Prenatal diagnosis of recurrent Meckel syndrome.
Int J Gynaecol Obstet 1992; 39: 327–332.
34 Parelkar SV, Kapadnis SP, Sanghvi BV, Joshi PB, Mundada D, Oak SN: Meckel-Gruber
Syndrome: a are and lethal anomaly with review of literature. J Pediatr Neurosci 2013;
8: 154–157.
35 Paavola P, Salonen R, Baumer A et al: Clinical and genetic heterogeneity in Meckel
syndrome. Hum Genet 1997; 101: 88–92.
36 Szymanska K, Berry I, Logan CV et al: Founder mutations and genotype-phenotype
correlations in Meckel-Gruber Syndrome and associated ciliopathies. Cilia 2012;
1: 18.
37 Khaddour R, Smith U, Baala L et al: Spectrum of MKS1 and MKS3 mutations in
Meckel syndrome: a genotype-phenotype correlation. Mutation in brief #960. Online.
Hum Mutat 2007; 28: 523–524.
38 Sepulveda W, Sebire NJ, Souka A, Snijders RJ, Nicolaides KH: Diagnosis of the
Meckel-Gruber Syndrome at eleven to fourteen weeks’ gestation. Am J Obstet Gynecol
1997; 176: 316–319.
39 Behairy NH, Talaat S, Saleem SN, El-Raouf MA: Magnetic resonance imaging in fetal
anomalies: what does it add to 3D and 4D US? Eur J Radio 2010; 74: 250–255.
Meckel-Gruber Syndrome
I Barisic et al
7
European Journal of Human Genetics
